Centre Hospitalier Universitaire Vaudoise, Service of Radiation Oncology, Department of Oncology, University of Lausanne, AGORA Center for Cancer Research, Swiss Cancer Center Leman, 1012-Lausanne, Switzerland.
Centre Hospitalier Universitaire Vaudoise, Service of Radiation Oncology, Department of Oncology, University of Lausanne, 1012-Lausanne, Switzerland.
Br J Radiol. 2024 Aug 1;97(1160):1378-1390. doi: 10.1093/bjr/tqae100.
Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment; yet their efficacy remains variable across patients. This review delves into the intricate interplay of tumour characteristics contributing to resistance against ICI therapy and suggests that combining with radiotherapy holds promise. Radiation, known for its ability to trigger immunogenic cell death and foster an in situ vaccination effect, may counteract these resistance mechanisms, enhancing ICI response and patient outcomes. However, particularly when delivered at high-dose, it may trigger immunosuppressive mechanism and consequent side-effects. Notably, low-dose radiotherapy (LDRT), with its capacity for tumour reprogramming and reduced side effects, offers the potential for widespread application. Preclinical and clinical studies have shown encouraging results in this regard.
免疫检查点抑制剂 (ICI) 彻底改变了癌症治疗方法；然而，它们在患者中的疗效仍然存在差异。这篇综述深入探讨了导致对 ICI 治疗产生耐药性的肿瘤特征的复杂相互作用，并表明与放射治疗相结合具有广阔的前景。众所周知，放射治疗能够引发免疫原性细胞死亡并促进原位疫苗效应，可能会对抗这些耐药机制，增强 ICI 反应和患者的治疗效果。然而，特别是在高剂量下，它可能会引发免疫抑制机制和相应的副作用。值得注意的是，低剂量放射治疗 (LDRT) 具有肿瘤重编程和减少副作用的能力，为广泛应用提供了潜力。临床前和临床研究在这方面显示出了令人鼓舞的结果。
